GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Takeda Pharmaceutical Co Ltd ADR TAK · USD

Health Care · US listing · 🇺🇸 United States

Compare

21.09

+0.33%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$29.99bn

FY2017FY2026

Net income

$1.28bn

FY2017FY2026

Free cash flow

$3.94bn

FY2017FY2026

Shareholders' equity

$49.02bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$29.99bn$28.76bn$26.77bn$25.29bn$22.41bn$20.08bn$20.66bn$13.17bn$11.12bn$10.87bn
Research and development$4.50bn$4.58bn$4.58bn$3.98bn$3.30bn$2.86bn$3.09bn$2.31bn$2.04bn$1.96bn
Operating income$3.60bn$2.15bn$3.14bn$3.08bn$2.89bn$3.20bn$630.4m$978.5m$1.52bn$978.6m
Net income$1.28bn$677.6m$904.5m$1.99bn$1.44bn$2.36bn$277.8m$685.1m$1.17bn$721.6m
Diluted earnings per share0.400.210.290.630.460.750.090.220.740.46

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$97.44bn$89.46bn$94.86bn$87.63bn$82.74bn$81.07bn$80.50bn$87.10bn$25.78bn$27.35bn
Cash and short-term investments$3.75bn$2.55bn$2.97bn$3.48bn$5.49bn$6.30bn$4.10bn$4.55bn$2.36bn$2.36bn
Total liabilities$48.42bn$45.91bn$49.19bn$47.74bn$47.05bn$48.56bn$50.81bn$54.68bn$13.12bn$15.11bn
Debt$30.66bn$28.35bn$30.41bn$27.51bn$27.28bn$29.10bn$31.98bn$36.11bn$6.19bn$7.19bn
Shareholders' equity$49.02bn$43.54bn$45.66bn$39.89bn$35.68bn$32.48bn$29.66bn$32.39bn$12.54bn$11.89bn
Shares outstanding3,209m3,205m3,170m3,170m3,141m3,150m3,151m3,115m1,577m1,573m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations$6.54bn$6.64bn$4.50bn$6.13bn$7.05bn$6.35bn$4.20bn$2.06bn$2.37bn$1.64bn
Capital spending−$2.60bn−$2.38bn−$3.02bn−$3.98bn−$1.17bn−$1.48bn−$1.37bn−$842.0m−$805.3m−$703.4m
Free cash flow$3.94bn$4.25bn$1.48bn$2.16bn$5.88bn$4.86bn$2.84bn$1.22bn$1.57bn$937.6m
Dividends paid−$1.96bn−$1.90bn−$1.80bn−$1.75bn−$1.78bn−$1.78bn−$1.77bn−$897.5m−$890.9m−$889.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$7.66bn$7.00bn$7.62bn$6.99bn$6.95bn$6.61bn$7.18bn$7.38bn
Operating income$1.26bn$298.5m$1.22bn$433.2m$1.16bn−$470.3m$420.3m$1.16bn
Net income$710.7m−$155.5m$662.4m−$74.1m$780.0m−$647.9m$149.4m$577.9m
Diluted earnings per share0.22-0.050.21-0.020.24-0.200.050.18
Cash from operations$801.0m$467.0m$2.34bn$2.37bn$1.35bn$1.39bn$2.41bn$1.76bn
Capital spending−$337.0m−$404.0m−$1.40bn−$331.0m−$471.0m−$582.0m−$355.0m−$580.0m
Free cash flow$464.0m$63.0m$947.0m$2.04bn$881.0m$812.0m$2.05bn$1.18bn
Total assets$98.34bn$97.44bn$96.81bn$90.85bn$87.93bn$89.46bn$94.85bn$91.50bn
Cash and short-term investments$3.31bn$3.75bn$4.78bn$4.64bn$2.63bn$2.55bn$3.31bn$5.69bn
Debt$31.02bn$30.66bn$30.47bn$29.17bn$28.29bn$28.35bn$30.39bn$31.71bn
Shareholders' equity$47.45bn$49.02bn$48.02bn$44.77bn$43.10bn$43.54bn$46.57bn$43.45bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.9%8.4%10.2%
Operating income5.3%2.4%15.9%
Net income-13.8%-11.6%9.8%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin9.8%10.8%11.8%10.4%
Net margin3.3%4.4%5.6%5.4%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings53.073.746.422.733.918.2206.589.722.662.0
Price to sales2.31.71.61.82.22.12.84.72.44.1

Market value over time

31 Oct 2016 to 16 Sept 2026, in USD

$35.11bn$59.82bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return13%-5%-8%8%-25%-7%20%-41%38%-17%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.